Focus: Coherus Oncology is a mid-cap biotech focused on oncology biologics and biosimilars, headquartered in Redwood City, CA with a diversified pipeline spanning immuno-oncology, solid tumors, and immunology indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
6 added, 3 removed. Backfill posture.
Coherus offers exposure to a growing oncology/immunology portfolio with partnership validation, but financial instability and early-stage pipeline concentration make this a higher-risk career choice for those seeking stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Most advanced marketed asset with Phase 2-4 programs across multiple oncology indications, appearing in 5+ pipeline entries.
Help build intelligence for Coherus Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Coherus Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biosimilar program in Phase 3 for RA and psoriasis, positioning Coherus in immunology adjacent to core oncology focus.
Marketed biosimilar asset with ongoing clinical utility in supportive oncology care.
Six biotech companies advancing the next generation of prostate cancer therapies - Labiotech.eu
Six biotech companies advancing the next generation of prostate cancer therapies Labiotech.eu
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - simplywall.st
Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses simplywall.st
8-K Filing: Coherus Oncology, Inc. (CHRS) (CIK 0001512762) — EX-99.1
EX-99.1
8-K Filing: Keros Therapeutics, Inc. (KROS) (CIK 0001664710) — EX-99.1
EX-99.1
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) Seeking Alpha
More drugmakers are turning to cancer combos. Will it help patients live longer? - Pharma Voice
More drugmakers are turning to cancer combos. Will it help patients live longer? Pharma Voice
Showing 6 of 9 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo